Challenges and Strategic Approaches to Biosimilar Development
Track
:
Track 02: Project/Portfolio Management and Strategic Planning
Program Code:
343
Date:
Wednesday, June 26, 2013
Time:
1:45 PM to 3:15 PM
EST
Location:
104AB
CHAIR
:
Jayanthi Reddy, MBA,MS,PMP (SCHNON), Director and Biologics Pipeline Leader,Global Project Management, Merck & Co., Inc., United States
Jay has over 18 years of pharmaceutical industry experience and over 10 years of project Management experience. She is currently the franchise lead for Biologics and the Neuroscience franchise within the Project Management group at Merck.
SPEAKER
(S):
Qinghai Zhao, (SPKNON), Director, Protein Sciences, Teva BioPharmaceuticals USA, United States
Andrew J Rankin, (SPKNON), Vice President, Biopharmaceuticals, Prescient Life Sciences, United States
With +20 yrs in the pharma industry, Dr. Andy Rankin is VP, Biopharmaceuticals at Prescient Life Sciences, consulting for multiple global pharma & biotechs in medicines development & commercial strategies, particularly in the oncology & biosimilars practices.
Steve Farrand, PhD,MSc (SPKNON), Vice President and Head Bioprocess Development, Merck Research Laboratories, United States
With +30 yrs in the biotech industry, Dr. Steve Farrand has been leading Merck’s BioProcess Development group located in NJ & Switzerland since 2004, having previously been with Schering-Plough in its Ireland & Singapore facilities. BSc in Microbiology, PhD in Biochemistry.
Description
This session will focus on understanding the strategic questions companies are facing when developing biosimilars and the drug development approaches that are being adopted. Case studies will be provided followed by an open forum discussion.